Oncotarget:缺血性卒中患者细胞免疫及炎症因子的变化

2016-10-25 MedSci MedSci原创

本研究旨在探讨缺血性卒中后细胞免疫系统和循环中炎症标志物的动态变化。从96例和99例年龄匹配的对照组收集血液,检测淋巴细胞亚群和炎症标志物。研究者观察到卒中患者在在1天,3天和7天,B细胞、Th细胞、细胞毒性T细胞,NK细胞减少,调节性T(Treg)增加的细胞。脑卒中各时间点血清TNF-α水平、C反应蛋白(CRP)、IL-4、IL-6、IL-10、IL-17、IL-23、TGF-β升高,而血清IF

本研究旨在探讨缺血性卒中后细胞免疫系统和循环中炎症标志物的动态变化。

从96例和99例年龄匹配的对照组收集血液,检测淋巴细胞亚群和炎症标志物。

研究者观察到卒中患者在在1天,3天和7天,B细胞、Th细胞、细胞毒性T细胞,NK细胞减少,调节性T(Treg)增加的细胞。脑卒中各时间点血清TNF-α水平、C反应蛋白(CRP)、IL-4、IL-6、IL-10、IL-17、IL-23、TGF-β升高,而血清IFN-γ下降。感染和非感染的卒中患者淋巴细胞亚群和炎症标志物呈现出类似的趋势。校正国立卫生研究院卒中量表(NIHSS)后,研究者发现前循环和后循环的卒中患者在各时间点淋巴细胞亚群变化没差异。卒中后3天脾体积与B细胞、Th细胞和细胞毒性T细胞的百分比呈正相关,但与Treg细胞呈负相关。感染与第三天脾体积、白细胞计数,Treg细胞百分比及血清CRP、IL-10和IFN-γ相关。病灶体积与第三天CRP、IL-6、IL-23呈正相关,但与IFN-γ呈负相关。NIHSS与IL-6和IL-10呈正相关。

缺血性卒中对全身性免疫系统有深远的影响,这可能可以解释卒中患者感染的易感性增加。

原始出处:

Jiang C, Kong W, et al. Changes in the cellular immune system and circulating inflammatory markers of stroke patients. Oncotarget. 2016 Sep 22.


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1892800, encodeId=852b189280098, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 11 02:41:00 CST 2017, time=2017-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806112, encodeId=9c8f180611284, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jul 09 00:41:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720133, encodeId=77b61e201330a, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Jun 27 19:41:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010354, encodeId=27342010354b0, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Aug 21 18:41:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795335, encodeId=96a21e95335ca, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Fri Feb 10 11:41:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407571, encodeId=6ebf140e5717c, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Thu Oct 27 11:41:00 CST 2016, time=2016-10-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1892800, encodeId=852b189280098, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 11 02:41:00 CST 2017, time=2017-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806112, encodeId=9c8f180611284, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jul 09 00:41:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720133, encodeId=77b61e201330a, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Jun 27 19:41:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010354, encodeId=27342010354b0, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Aug 21 18:41:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795335, encodeId=96a21e95335ca, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Fri Feb 10 11:41:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407571, encodeId=6ebf140e5717c, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Thu Oct 27 11:41:00 CST 2016, time=2016-10-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1892800, encodeId=852b189280098, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 11 02:41:00 CST 2017, time=2017-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806112, encodeId=9c8f180611284, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jul 09 00:41:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720133, encodeId=77b61e201330a, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Jun 27 19:41:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010354, encodeId=27342010354b0, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Aug 21 18:41:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795335, encodeId=96a21e95335ca, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Fri Feb 10 11:41:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407571, encodeId=6ebf140e5717c, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Thu Oct 27 11:41:00 CST 2016, time=2016-10-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1892800, encodeId=852b189280098, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 11 02:41:00 CST 2017, time=2017-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806112, encodeId=9c8f180611284, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jul 09 00:41:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720133, encodeId=77b61e201330a, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Jun 27 19:41:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010354, encodeId=27342010354b0, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Aug 21 18:41:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795335, encodeId=96a21e95335ca, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Fri Feb 10 11:41:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407571, encodeId=6ebf140e5717c, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Thu Oct 27 11:41:00 CST 2016, time=2016-10-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1892800, encodeId=852b189280098, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 11 02:41:00 CST 2017, time=2017-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806112, encodeId=9c8f180611284, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jul 09 00:41:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720133, encodeId=77b61e201330a, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Jun 27 19:41:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010354, encodeId=27342010354b0, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Aug 21 18:41:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795335, encodeId=96a21e95335ca, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Fri Feb 10 11:41:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407571, encodeId=6ebf140e5717c, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Thu Oct 27 11:41:00 CST 2016, time=2016-10-27, status=1, ipAttribution=)]
    2017-02-10 闆锋旦
  6. [GetPortalCommentsPageByObjectIdResponse(id=1892800, encodeId=852b189280098, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 11 02:41:00 CST 2017, time=2017-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806112, encodeId=9c8f180611284, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jul 09 00:41:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720133, encodeId=77b61e201330a, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Jun 27 19:41:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010354, encodeId=27342010354b0, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Mon Aug 21 18:41:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795335, encodeId=96a21e95335ca, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Fri Feb 10 11:41:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407571, encodeId=6ebf140e5717c, content=<a href='/topic/show?id=f150e779256' target=_blank style='color:#2F92EE;'>#细胞免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77792, encryptionId=f150e779256, topicName=细胞免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9362684728, createdName=tulenzi, createdTime=Thu Oct 27 11:41:00 CST 2016, time=2016-10-27, status=1, ipAttribution=)]

相关资讯

Stroke:缺血性卒中或短暂性脑缺血发作患者发生脑微梗死危险因素有哪些?

最近有研究表明,脑微梗死(CMIs)可在体内使用3.0特斯拉(T)磁共振成像检测。研究人员调查了在缺血性卒中或短暂性脑缺血发作患者中,使用3.0T磁共振成像检测的大脑皮层CMIs的患病率,危险因素,和纵向认知结果。 该研究共包括231例接受3.0T磁共振成像的患者。蒙特利尔认知评估被用来评估总体认知功能和认知域(记忆,语言和注意视觉空间和执行功能)。蒙特利尔认知评分评估了基线和卒中/短暂

Stroke:缺血性卒中和短暂性脑缺血发作患者有很高的房颤风险

与缺血性卒中(IS)相比,房颤(AF)与短暂性脑缺血发作(TIA)之间的联系还没有被建立。该研究的目的是评估与IS患者相比,TIA患者发生房颤的比例,这些患者的特点,以及和二级预防治疗。 来自瑞典的研究人员分析了从2011年7月至2013年6月期间登记的TIA和IS事件基于医院的数据,这些数据从瑞典卒中注册(Riksstroke)获得。该研究也应用了基于时间的TIA定义(症状的持续时间&

Stroke:缺血性卒中护理中的男女“不平等”

卒中护理中,包括溶栓治疗和早期入院的性别特异性差异都经过了报道。

Neurology:确切数据告诉你肥胖与卒中之间的关系

目的该研究的目的在于通过收集全球数据比较BMI与缺血性卒中和出血性卒中风险之间的关联。方法研究人员在1996-2001年招募了130万名无卒中病史的英国女性(平均年龄为57岁),并对她们进行了持续随访,收集她们的住院信息和死亡信息。之后使用Cox回归分析来评估BMI与参与者患缺血性和出血性卒中(脑出血或蛛网膜下腔出血)风险之间的关系。此外,研究人员收集所有相关前瞻性研究进行荟萃分析。结果平均随访时

JAHA:不同急性冠脉综合征,IS发生的风险不同

背景:既往研究显示心肌梗死后缺血性卒中的风险增加(IS),但是其长期的风险和是否与心脏损伤直接损伤相关尚不清楚。研究者假设如果有证据证明心肌损伤,急性冠脉综合征后IS的风险明显高于非心肌损伤者,心肌损伤如ST段抬高型心肌梗死(STEMI)和非ST段抬高型心肌梗死,表明心肌未损伤,如不稳定型心绞痛。方法和结果:纳入数据为2008和2011期间,利福尼亚非联邦急性护理医院急诊和住院部。使用适当的国际疾

Br J Haematol:女性需警惕!多次妊娠失败可增加缺血性卒中和心肌梗死的发生风险

近日,来自莱顿大学医学中心的一项新的研究发现表明,妊娠失败可增加年轻女性动脉血栓形成的风险,该研究已发表于British journal of haematology。 研究共纳入了缺血性卒中(IS)或心肌梗死(MI)且至少妊娠一次的女性(18~50岁)与妊娠失败对照组进行对比。计算比值比(OR)值与95%置信区间(CI),校正匹配变量、心血管危险因子、心血管病家族史和存在抗磷脂抗体,以得出